Shared Genetics and Risk Factors Between Epilepsy and Psychiatric Disease

癫痫和精神疾病之间的共同遗传学和危险因素

基本信息

  • 批准号:
    10533822
  • 负责人:
  • 金额:
    $ 52.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-01-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

1 in 26 people in the US have a diagnosis of epilepsy, characterized by seizures resulting from abnormal electrical discharges in the brain. These seizures have heterogeneous physical manifestations (convulsions, sensory disturbances, or loss of consciousness) and are observed at markedly increased frequencies in persons with psychiatric and neurodevelopmental disorders. At least a third of persons with epilepsy experience additional seizures whilst on treatment. We do not understand the pathogenesis of common forms of epilepsy not due to obvious injury or severe mutations; whether different forms of epilepsy are driven by different pathogenic mechanisms; or whether these mechanisms are (partly) shared with other diseases and thus drive the observed comorbidity. This limits clinical management options, accurate prognosis including the likelihood of comorbid psychiatric disease, and development of new therapies. Epidemiological studies of epilepsy could uncover outcome predictors, and human genetic studies could uncover both causal genes and whether these also contribute risk of other diseases; these results would provide a substrate both for discovering pathogenic mechanisms and for predicting patient outcomes. However, these activities require large cohorts with both lifelong medical data and DNA material, which are not available in the US. We have a unique opportunity to overcome this barrier using the population resources available in Denmark: we can retrieve and genotype DNA from neonatal bloodspots for ~12,000 persons with epilepsy via the Danish National Hospital Register, and match these to life-long clinical data and life events. By incorporating data from previous genetic studies of epilepsy and of neuropsychiatric disease, and by using our state-of-the-art methods to identify causal genes from such data, we can thus (1) perform a well-powered genetic study in epilepsy and identify causal genes; (2) test and validate predictors of outcomes, including comorbid psychiatric disease in persons with epilepsy, and whether they are causal; (3) establish if comorbid psychiatric disease shares heritability, and thus a pathological basis, with epilepsy. Specifically, we will: 1. Identify genetic variants predisposing to epilepsy and the genes they affect. Use the heritability information in genome-wide variation to assess if epilepsy subtypes are driven by the same pathogenic mechanisms, and if these are shared with comorbid psychiatric disease. 2. Identify outcome predictors for persons with epilepsy, and their genetic determinants. These studies will uncover genes driving epilepsy pathogenesis, and establish if the subtypes of common, complex epilepsy share these mechanisms. Our findings will be crucial to any future preventive or intervention strategies, as they will enable clinicians to predict the likelihood of comorbid psychiatric disease in persons with epilepsy at the time of diagnosis, and suggest targets for developing new anti-seizure medications.
在美国,每26人中就有1人被诊断为癫痫,其特征是异常导致的癫痫发作 大脑中的电放电。这些癫痫发作具有不同的物理表现(抽搐、 感觉障碍或意识丧失),并以显著增加的频率观察到 有精神和神经发育障碍的人。至少三分之一的癫痫患者 在治疗过程中经历额外的癫痫发作。我们不了解常见形式的发病机制 指不是由于明显的损伤或严重的突变引起的癫痫;不同形式的癫痫是否由 不同的致病机制;或者这些机制是否(部分)与其他疾病和 从而推动观察到的共病。这限制了临床治疗选择和准确的预后,包括 合并精神疾病的可能性,以及新疗法的开发。 癫痫的流行病学研究可以揭示预后预测因素,而人类基因研究可以 发现两个原因基因以及这些基因是否也会增加其他疾病的风险;这些结果将 为发现致病机制和预测患者预后提供了底物。 然而,这些活动需要拥有终身医学数据和DNA材料的大量队列,而这些数据并不是 在美国上市。我们有一个独特的机会来克服这个障碍,利用人口资源 在丹麦可用:我们可以从新生儿血斑中提取DNA并对其进行基因分型,适用于约12,000名患有 通过丹麦国家医院登记簿,并将这些数据与终身临床数据和生活事件进行匹配。通过 整合了先前癫痫和神经精神疾病基因研究的数据,并使用我们的 最先进的方法从这样的数据中识别因果基因,因此我们可以(1)执行强大的 癫痫的遗传学研究和确定致病基因;(2)测试和验证结果的预测因素,包括 癫痫患者的共病精神疾病及其是否有因果关系;(3)确定是否有共病 精神疾病与癫痫有共同的遗传性,因此也是一个病理学基础。具体来说,我们会: 1.确定易患癫痫的基因变异及其影响的基因。利用可遗传性 全基因组变异中的信息以评估癫痫亚型是否由相同的致病因素驱动 机制,如果这些与共病的精神疾病共享。 2.确定癫痫患者的预后预测因素及其遗传决定因素。 这些研究将揭示驱动癫痫发病机制的基因,并确定常见的、 复杂的癫痫有相同的机制。我们的发现对未来的任何预防或干预都是至关重要的 策略,因为它们将使临床医生能够预测患有以下疾病的人并发精神疾病的可能性 在诊断时癫痫,并建议为开发新的抗癫痫药物的目标。

项目成果

期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events.
多基因风险评分作为一生中和未特指癫痫发作事件后癫痫风险的标志。
  • DOI:
    10.1101/2023.11.27.23297542
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Heyne,HenrikeO;Pajuste,Fanny-Dhelia;Wanner,Julian;Onwuchekwa,JenniferIDaniel;Mägi,Reedik;Palotie,Aarno;FinnGen,EstonianBiobankresearchteam;Kälviainen,Reetta;Daly,MarkJ
  • 通讯作者:
    Daly,MarkJ
Birth characteristics and risk of febrile seizures.
  • DOI:
    10.1111/ane.13420
  • 发表时间:
    2021-07
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Christensen KJ;Dreier JW;Skotte L;Feenstra B;Grove J;Børglum A;Mitrovic M;Cotsapas C;Christensen J
  • 通讯作者:
    Christensen J
Seasonal Variation and Risk of Febrile Seizures: A Danish Nationwide Cohort Study.
  • DOI:
    10.1159/000522065
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    5.7
  • 作者:
    Christensen, Kirstine Juul;Dreier, Julie W.;Skotte, Line;Feenstra, Bjarke;Grove, Jakob;Borglum, Anders D.;Mitrovic, Mitja;Cotsapas, Chris;Christensen, Jakob
  • 通讯作者:
    Christensen, Jakob
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kristen Jennifer Brennand其他文献

Kristen Jennifer Brennand的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kristen Jennifer Brennand', 18)}}的其他基金

High-throughput in vivo and in vitro functional and multi-omics screens of neuropsychiatric and neurodevelopmental disorder risk genes
神经精神和神经发育障碍风险基因的高通量体内和体外功能和多组学筛选
  • 批准号:
    10643398
  • 财政年份:
    2023
  • 资助金额:
    $ 52.56万
  • 项目类别:
Modeling the interaction of physiological and environmental stressors on common variants to psychiatric traits
模拟生理和环境压力源对精神特征常见变异的相互作用
  • 批准号:
    10706811
  • 财政年份:
    2022
  • 资助金额:
    $ 52.56万
  • 项目类别:
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches
使用单细胞方法解决精神疾病基因的复杂选择性剪接
  • 批准号:
    10630216
  • 财政年份:
    2021
  • 资助金额:
    $ 52.56万
  • 项目类别:
Modeling the interaction of physiological and environmental stressors on common variants to psychiatric traits
模拟生理和环境压力源对精神特征常见变异的相互作用
  • 批准号:
    10337629
  • 财政年份:
    2021
  • 资助金额:
    $ 52.56万
  • 项目类别:
Resolving complex alternative splicing of psychiatric disease genes using single-cell approaches
使用单细胞方法解决精神疾病基因的复杂选择性剪接
  • 批准号:
    10462568
  • 财政年份:
    2021
  • 资助金额:
    $ 52.56万
  • 项目类别:
Critical assessment of DNA adenine methylation in brain cells from healthy aging and Alzheimer's disease
健康老龄化和阿尔茨海默病脑细胞 DNA 腺嘌呤甲基化的批判性评估
  • 批准号:
    10365337
  • 财政年份:
    2021
  • 资助金额:
    $ 52.56万
  • 项目类别:
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders
与神经发育障碍相关的多种基因被破坏后的功能趋同
  • 批准号:
    10626945
  • 财政年份:
    2021
  • 资助金额:
    $ 52.56万
  • 项目类别:
Functional convergence following disruption of diverse genes associated with neurodevelopmental disorders
与神经发育障碍相关的多种基因被破坏后的功能趋同
  • 批准号:
    10407989
  • 财政年份:
    2021
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease
新的网络生物学方法重新定位 FDA 批准的阿尔茨海默病药物
  • 批准号:
    10653036
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel Network Biology Approaches to Reposition FDA-approved Drugs for Alzheimer's Disease
新的网络生物学方法重新定位 FDA 批准的阿尔茨海默病药物
  • 批准号:
    10260473
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:

相似海外基金

Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10004277
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10475298
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10013749
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10693904
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Study on how anticonvulsants affect car driving
抗惊厥药如何影响汽车驾驶的研究
  • 批准号:
    20K17977
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10266034
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel Water-Soluble Adjunct Anticonvulsants for Nerve Agents
用于神经毒剂的新型水溶性辅助抗惊厥药
  • 批准号:
    10475109
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Novel pediatric anticonvulsants for nerve agents
用于神经毒剂的新型儿科抗惊厥药
  • 批准号:
    10248384
  • 财政年份:
    2020
  • 资助金额:
    $ 52.56万
  • 项目类别:
Prevention of neuropathic pain by antidepressants and anticonvulsants: in vivo patch-clamp analysis
抗抑郁药和抗惊厥药预防神经性疼痛:体内膜片钳分析
  • 批准号:
    24592355
  • 财政年份:
    2012
  • 资助金额:
    $ 52.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Anticonvulsants, ischemic seizures and regeneration in the immature brain
抗惊厥药、缺血性癫痫发作和未成熟大脑的再生
  • 批准号:
    8492175
  • 财政年份:
    2009
  • 资助金额:
    $ 52.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了